Last reviewed · How we verify

NCT01590069

Aerosolized Aldesleukin in Treating Patients With Lung Metastases

Active, enrolled Phase 1 Last updated 16 April 2026
What this trial tests

Phase 1 trial testing Aerosolized Aldesleukin in Metastatic Malignant Neoplasm in the Lung in 70 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
28 June 2012
Primary endpoint
30 April 2026
30 April 2026

Quick facts

Lead sponsorM.D. Anderson Cancer Center
PhasePhase 1
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment70
Start date28 June 2012
Primary completion30 April 2026
Estimated completion30 April 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 12 to 50, any sex, with Metastatic Malignant Neoplasm in the Lung or Metastatic Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/II trial studies the side effects and best dose of aerosolized aldesleukin and to see how well it works in treating patients with cancer that has spread from the original tumor to the lungs. Biological therapies, such as aerosolized aldesleukin, may stimulate or suppress the immune system in different ways and stop tumor cells from growing.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Pulmonary Delivery of Biological Drugs.
    Liang W, Pan HW, Vllasaliu D, Lam JKW. · · 2020 · cited 115× · PMID 33114726 · DOI 10.3390/pharmaceutics12111025
  2. Recent and Ongoing Research into Metastatic Osteosarcoma Treatments.
    Harris MA, Hawkins CJ. · · 2022 · cited 100× · PMID 35409176 · DOI 10.3390/ijms23073817
  3. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
    Shaikh AB, Li F, Li M, He B, et al · · 2016 · cited 89× · PMID 27058531 · DOI 10.3390/ijms17040506
  4. Developing inhaled protein therapeutics for lung diseases.
    Matthews AA, Ee PLR, Ge R. · · 2020 · cited 57× · PMID 34765995 · DOI 10.1186/s43556-020-00014-z
  5. Trial Watch: Immunostimulatory cytokines.
    Vacchelli E, Eggermont A, Fridman WH, Galon J, et al · · 2013 · cited 47× · PMID 24073369 · DOI 10.4161/onci.24850
  6. Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.
    Rivera-Valentin RK, Zhu L, Hughes DP. · · 2015 · cited 31× · PMID 26002157 · DOI 10.1007/s40272-015-0134-4
  7. Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities.
    Du X, Wei H, Zhang B, Wang B, et al · · 2023 · cited 23× · PMID 37197432 · DOI 10.3389/fonc.2023.1117867
  8. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
    Omer N, Nicholls W, Ruegg B, Souza-Fonseca-Guimaraes F, et al · · 2021 · cited 18× · PMID 34804076 · DOI 10.3389/fimmu.2021.791206

Verify or expand the search:

Other recruiting trials for Metastatic Malignant Neoplasm in the Lung

Currently open trials in the same condition.

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01590069.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing